vs

Side-by-side financial comparison of AMERICAN WOODMARK CORP (AMWD) and Ascendis Pharma A/S (ASND). Click either name above to swap in a different company.

AMERICAN WOODMARK CORP is the larger business by last-quarter revenue ($394.6M vs $267.3M, roughly 1.5× Ascendis Pharma A/S). On growth, Ascendis Pharma A/S posted the faster year-over-year revenue change (42.3% vs -12.8%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs -3.3%).

American Woodmark Corporation is a kitchen and bath cabinet manufacturer headquartered in Winchester, Virginia. The company operates several manufacturing facilities and service centers. The manufacturing facilities are located in Arizona, Georgia, Indiana, Kentucky, Maryland, Tennessee, Virginia, and West Virginia with service centers being located throughout the country.

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

AMWD vs ASND — Head-to-Head

Bigger by revenue
AMWD
AMWD
1.5× larger
AMWD
$394.6M
$267.3M
ASND
Growing faster (revenue YoY)
ASND
ASND
+55.1% gap
ASND
42.3%
-12.8%
AMWD
Faster 2-yr revenue CAGR
ASND
ASND
Annualised
ASND
60.7%
-3.3%
AMWD

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
AMWD
AMWD
ASND
ASND
Revenue
$394.6M
$267.3M
Net Profit
$6.1M
Gross Margin
15.2%
90.5%
Operating Margin
3.1%
Net Margin
1.5%
Revenue YoY
-12.8%
42.3%
Net Profit YoY
-78.0%
EPS (diluted)
$0.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMWD
AMWD
ASND
ASND
Q4 25
$394.6M
$267.3M
Q3 25
$403.0M
$230.7M
Q2 25
$400.4M
$170.7M
Q1 25
$397.6M
$109.0M
Q4 24
$452.5M
$187.8M
Q3 24
$459.1M
$62.5M
Q2 24
$453.3M
$38.9M
Q1 24
$422.1M
$103.6M
Net Profit
AMWD
AMWD
ASND
ASND
Q4 25
$6.1M
Q3 25
$14.6M
$-65.9M
Q2 25
$25.6M
$-42.0M
Q1 25
$16.6M
$-102.2M
Q4 24
$27.7M
Q3 24
$29.6M
$-107.1M
Q2 24
$26.8M
$-118.1M
Q1 24
$21.2M
$-141.5M
Gross Margin
AMWD
AMWD
ASND
ASND
Q4 25
15.2%
90.5%
Q3 25
16.7%
89.5%
Q2 25
17.0%
80.1%
Q1 25
15.0%
82.6%
Q4 24
18.9%
91.9%
Q3 24
20.2%
80.6%
Q2 24
18.6%
68.2%
Q1 24
19.2%
92.1%
Operating Margin
AMWD
AMWD
ASND
ASND
Q4 25
3.1%
Q3 25
5.0%
5.1%
Q2 25
7.4%
-33.5%
Q1 25
5.3%
-103.2%
Q4 24
9.4%
Q3 24
10.2%
-167.3%
Q2 24
8.4%
-370.2%
Q1 24
6.6%
-51.2%
Net Margin
AMWD
AMWD
ASND
ASND
Q4 25
1.5%
Q3 25
3.6%
-28.5%
Q2 25
6.4%
-24.6%
Q1 25
4.2%
-93.7%
Q4 24
6.1%
Q3 24
6.5%
-171.5%
Q2 24
5.9%
-303.9%
Q1 24
5.0%
-136.6%
EPS (diluted)
AMWD
AMWD
ASND
ASND
Q4 25
$0.42
Q3 25
$1.00
Q2 25
$1.73
Q1 25
$1.09
Q4 24
$1.79
Q3 24
$1.89
Q2 24
$1.70
Q1 24
$1.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMWD
AMWD
ASND
ASND
Cash + ST InvestmentsLiquidity on hand
$52.1M
$665.3M
Total DebtLower is stronger
$363.3M
Stockholders' EquityBook value
$928.2M
$-175.8M
Total Assets
$1.6B
$1.4B
Debt / EquityLower = less leverage
0.39×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMWD
AMWD
ASND
ASND
Q4 25
$52.1M
$665.3M
Q3 25
$54.9M
$582.2M
Q2 25
$48.2M
$533.6M
Q1 25
$43.5M
$559.4M
Q4 24
$56.7M
$604.3M
Q3 24
$89.3M
$675.6M
Q2 24
$87.4M
$279.4M
Q1 24
$97.8M
$345.9M
Total Debt
AMWD
AMWD
ASND
ASND
Q4 25
$363.3M
Q3 25
$364.8M
Q2 25
$365.8M
Q1 25
$367.3M
Q4 24
$368.0M
Q3 24
$372.2M
Q2 24
$371.8M
Q1 24
$371.3M
Stockholders' Equity
AMWD
AMWD
ASND
ASND
Q4 25
$928.2M
$-175.8M
Q3 25
$920.3M
$-188.0M
Q2 25
$916.0M
$-202.6M
Q1 25
$919.6M
$-205.0M
Q4 24
$915.1M
$-114.2M
Q3 24
$913.8M
$-105.1M
Q2 24
$910.4M
$-346.8M
Q1 24
$896.9M
$-257.2M
Total Assets
AMWD
AMWD
ASND
ASND
Q4 25
$1.6B
$1.4B
Q3 25
$1.6B
$1.2B
Q2 25
$1.6B
$1.2B
Q1 25
$1.6B
$1.1B
Q4 24
$1.6B
$1.3B
Q3 24
$1.6B
$1.2B
Q2 24
$1.6B
$819.0M
Q1 24
$1.6B
$866.7M
Debt / Equity
AMWD
AMWD
ASND
ASND
Q4 25
0.39×
Q3 25
0.40×
Q2 25
0.40×
Q1 25
0.40×
Q4 24
0.40×
Q3 24
0.41×
Q2 24
0.41×
Q1 24
0.41×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMWD
AMWD
ASND
ASND
Operating Cash FlowLast quarter
$11.2M
$58.2M
Free Cash FlowOCF − Capex
$638.0K
FCF MarginFCF / Revenue
0.2%
Capex IntensityCapex / Revenue
2.7%
Cash ConversionOCF / Net Profit
1.83×
TTM Free Cash FlowTrailing 4 quarters
$64.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMWD
AMWD
ASND
ASND
Q4 25
$11.2M
$58.2M
Q3 25
$33.1M
Q2 25
$44.8M
Q1 25
$11.0M
$-15.5M
Q4 24
$11.9M
$-330.7M
Q3 24
$40.8M
Q2 24
$43.3M
Q1 24
$43.7M
$-109.7M
Free Cash Flow
AMWD
AMWD
ASND
ASND
Q4 25
$638.0K
Q3 25
$25.3M
Q2 25
$35.8M
Q1 25
$2.3M
Q4 24
$1.1M
Q3 24
$29.5M
Q2 24
$7.2M
Q1 24
$22.1M
FCF Margin
AMWD
AMWD
ASND
ASND
Q4 25
0.2%
Q3 25
6.3%
Q2 25
8.9%
Q1 25
0.6%
Q4 24
0.2%
Q3 24
6.4%
Q2 24
1.6%
Q1 24
5.2%
Capex Intensity
AMWD
AMWD
ASND
ASND
Q4 25
2.7%
Q3 25
1.9%
Q2 25
2.2%
Q1 25
2.2%
Q4 24
2.4%
Q3 24
2.5%
Q2 24
8.0%
Q1 24
5.1%
Cash Conversion
AMWD
AMWD
ASND
ASND
Q4 25
1.83×
Q3 25
2.27×
Q2 25
1.75×
Q1 25
0.66×
Q4 24
0.43×
Q3 24
1.38×
Q2 24
1.62×
Q1 24
2.06×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMWD
AMWD

Home Center Retailers$166.7M42%
Builders$164.7M42%
Independent Dealersand Distributors$63.2M16%

ASND
ASND

Segment breakdown not available.

Related Comparisons